Skip to main content
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

Newsletter February 2012

Gene Therapy Net Banner
News: NVGCT launches new website
Since gene and cell therapy are closely related and actually intertwined scientific disciplines aiming at expanding and innovating the therapeutic arsenal for many so far incurable diseases, the Netherlands Society of Gene and Cell Therapy (NVGCT) now includes cell therapy in its name. Its new web site (, launched February 1, 2012, aims at fostering further development and communicating progress.

News: Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation And Requests Further Information From the CHMP
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, was informed on Friday January 27, 2012 after business hours that the European Commission's Standing Committee of the European Parliament discussed on Monday January 22, 2012 the implementation decision not to grant marketing authorization for Glybera (alipogene tiparvovec) as recommended by the Committee for Human Medicinal Products (CHMP). After the discussion no clear position in favor or against granting a marketing authorization for Glybera was reached. Instead the Standing Committee considered it necessary to request additional information to the CHMP in the European Medicines Agency (EMA). A formal vote by the Standing Committee will be made on review of the additional information. It is currently unclear when a final decision will be reached.

Company: Lysogene
LYSOGENE is a clinical stage pioneering biotechnology company engaged in providing once in a lifetime safe and efficient innovative gene therapy treatments for patients affected with severe neurological diseases.
With its first product into the clinic, aiming at treating a fatal pediatric disease (Sanfilippo Syndrome), LYSOGENE aims at expanding its extraordinary potential to other CNS indications with high unmet medical needs.
LYSOGENE’s business and economic model is based on avant-garde drug development methodologies focused on scientific and medical intelligence, regulatory streamlining, and genuine patient-turned drivers.


Conference: Spring Symposium of the Netherlands Society of Gene & Cell Therapy (NVCGT)

The Spring Symposium of the Netherlands Society of Gene & Cell Therapy which combines the second ATMP workshop will take place March 8 & 9, 2012, Heeze, The Netherlands (

Please take note of the following deadlines:

February 15
Deadline Abstract submission for Spring Symposium:
Submit abstracts to: This email address is being protected from spambots. You need JavaScript enabled to view it.

Deadline Early Registration Fee for NVGCT Spring Symposium incl ATMP workshop Please find registration and hotel reservation form.

NVGCT members: 1 day 35 euro, 2 days 60 euro
Non-members: 1 day 75 euro, 2 days 100 euro
Late registration or on site registration: addition of 25 euro.


- 8 - 9 March 2012, Spring Symposium of the Netherlands Society of Gene & Cell Therapy (NVGCT), Heeze, The Netherlands
- 9 March 2012, Annual conference of the British Society for Gene Therapy (BSGT), London, UK
- 15 - 17 March 2012, 18th Annual Meeting of the German Society for Gene Therapy (DG-GT), Frankfurt/Main, Germany
- 16 – 19 May 2012, American Society of Gene and Cell Therapy (ASGCT) 15th Annual Meeting, Philadelphia, PA
- 21 – 23 May 2012, 2012 World Gene Therapy Congress Europe, London, UK
- 5 – 8 June 2012, International Society for Cellular Therapy (ISCT) 18th Annual Meeting, Seattle, WA
- 28 – 30 June 2012, The 18th Annual Meeting of the Japan Society of Gene Therapy (JSGT), Kumamoto University, Kumamoto, Japan
- 5 – 6 October 2012, International Society for Cell & Gene Therapy of Cancer - 2012 Singapore Conference, Singapore
- 22 – 24 October 2012, International conference on Genetic Syndromes & Gene Therapy, Chicago
- 26 – 29 October 2012, European Society Of Gene & Cell Therapy (ESGCT) XXth annual meeting and the French Society of Cell and Gene Therapy (SFTCG) collaborative Congress 2012, Versailles, France


Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net and Chikungunya Virus Net.
To unsubscribe from the Newsletter, please login and edit your subscription details or contact us. You are currently registered as: {subtag:name}, email address: {subtag:email}.

Advertise on this site?